Regen BioPharma Inc (RGBPP) financial statements (2022 and earlier)

Company profile

Business Address 4700 SPRING ST #304
LA MESA, CA 91942
State of Incorp. NV
Fiscal Year End September 30
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

12/31/2021
TTM
9/30/2021
9/30/2020
9/30/2019
9/30/2018
9/30/2017
9/30/2016
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments353727 8827025
Cash and cash equivalents353727 8827025
Receivables24621910371810786
Prepaid expense41480083470
Other undisclosed current assets00  196727
Total current assets:6419941037943478207
Noncurrent Assets
Other undisclosed noncurrent assets942182020166466112
Total noncurrent assets:942182020166466112
TOTAL ASSETS:7351,21212399209944319
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:1,2671,2671,189972656591264
Accounts payable32911109281496241
Accrued liabilities      10
Employee-related liabilities44444133
Other undisclosed accounts payable and accrued liabilities1,2301,1711,07587657194(20)
Debt1101 0 107
Due to related parties0062890111143
Other undisclosed current liabilities9,22313,4216,2069,9428,0175,161285
Total current liabilities:10,49114,6987,45811,0038,6745,863799
Noncurrent Liabilities
Long-term debt and lease obligation    656332107
Long-term debt, excluding current maturities    656332107
Other undisclosed noncurrent liabilities   51  
Total noncurrent liabilities:   5657332107
Total liabilities:10,49114,6987,45811,0089,3316,196906
Stockholders' equity
Stockholders' equity attributable to parent, including:(9,804)(13,533)(7,335)(10,909)(9,122)(5,251)(587)
Common stock45643516060181414
Additional paid in capital9,7078,6448,3148,2627,5186,64318,961
Accumulated other comprehensive income (loss)    5388(80)
Accumulated deficit(20,704)(23,349)(16,584)(19,998)(17,457)(12,742)(20,224)
Other additional capital736736732729729729729
Other undisclosed stockholders' equity attributable to parent  4339181714
Other undisclosed stockholders' equity4848   0 
Total stockholders' equity:(9,756)(13,486)(7,335)(10,909)(9,122)(5,251)(587)
TOTAL LIABILITIES AND EQUITY:7351,21212399209944319

Income statement (P&L) ($ in thousands)

12/31/2021
TTM
9/30/2021
9/30/2020
9/30/2019
9/30/2018
9/30/2017
9/30/2016
Revenues1,99861110110100110100
Other income   2 51 
Cost of revenue(400)(216)(56)(202)(408)(649)(722)
Gross profit:1,598(155)54(92)(308)(539)(622)
Operating expenses(150)(156)(263)(664)(1,118)(1,972)(2,335)
Other undisclosed operating income110110     
Operating income (loss):1,558(201)(209)(757)(1,426)(2,511)(2,957)
Nonoperating income
(Investment Income, Nonoperating)
   1  19
Interest and debt expense(343)(292)(333)(295)(363)(99)(28)
Income (loss) before gain (loss) on sale of properties:1,215(492)(543)(1,051)(1,789)(2,610)(2,966)
Other undisclosed net loss(11,893)      
Net loss:(10,678)(492)(543)(1,051)(1,789)(2,610)(2,966)
Other undisclosed net income (loss) attributable to parent(1,164)(6,273)3,957(1,573)(2,926)(3,229)(4,784)
Net income (loss) attributable to parent:(11,842)(6,765)3,414(2,623)(4,715)(5,839)(7,751)
Other undisclosed net loss available to common stockholders, basic(254) (683)    
Net income (loss) available to common stockholders, diluted:(12,096)(6,765)2,732(2,623)(4,715)(5,839)(7,751)

Comprehensive Income ($ in thousands)

12/31/2021
TTM
9/30/2021
9/30/2020
9/30/2019
9/30/2018
9/30/2017
9/30/2016
Net loss:(10,678)(492)(543)(1,051)(1,789)(2,610)(2,966)
Other comprehensive income (loss)    (35)168(46)
Comprehensive loss:(10,678)(492)(543)(1,051)(1,824)(2,442)(3,013)
Other undisclosed comprehensive loss, net of tax, attributable to parent    (2,926)(3,229) 
Comprehensive loss, net of tax, attributable to parent:(10,678)(492)(543)(1,051)(4,750)(5,671)(3,013)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: